Bajaj Healthcare Unveils Investor Presentation, Showcasing Strong Financial Position and Diverse Operations

Bajaj HealthCare Limited (BHL) has released an investor presentation for its upcoming analyst and institutional investor meeting, scheduled for December 08-09, 2025. The presentation highlights the company's operations across multiple business verticals and its financial position.

Diverse Business Operations

BHL's operations span across several key areas:

API Manufacturing
Formulations
Alkaloid Processing
CDMO (Contract Development and Manufacturing Organization) Business

The company has established a global presence, with its products reaching over 60 countries worldwide.

Financial Position

Based on the latest balance sheet data, Bajaj Healthcare demonstrates the following financial metrics:

Financial Metric	Current Year (2025-03)	1 Year Ago (2024-03)	Change
Total Assets	₹833.00 crore	₹765.10 crore	8.87%
Current Assets	₹485.40 crore	₹404.50 crore	20.00%
Fixed Assets	₹238.40 crore	₹252.80 crore	-5.70%
Total Equity	₹466.20 crore	₹278.40 crore	67.46%
Current Liabilities	₹272.30 crore	₹402.10 crore	-32.28%

The company has shown changes in its financial position over the past year:

Asset Growth: Total assets increased by 8.87% to ₹833.00 crore.
Equity: Total equity rose by 67.46%, reaching ₹466.20 crore.
Liquidity: Current assets grew by 20% while current liabilities decreased by 32.28%.
Fixed Assets: A slight decrease of 5.70% in fixed assets was observed.

Investor Meeting Focus

The upcoming analyst and institutional investor meeting may cover:

Performance across different business verticals
Global market presence
CDMO partnerships and prospects
Financial position and growth strategies
Alkaloid processing operations and market potential

Investors and analysts will have the opportunity to gain insights into Bajaj Healthcare's operations, financial strategies, and outlook during the scheduled meeting.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.40%	-4.02%	-9.52%	-24.73%	-14.52%	+10.51%

Bajaj Healthcare Limited , a prominent player in the pharmaceutical sector, has announced its financial results for the second quarter of fiscal year 2026, showcasing robust performance despite challenging market conditions.

Key Financial Highlights

Particulars (₹ in Crore)	Q2 FY26	Q2 FY25	YoY Change	H1 FY26	H1 FY25	YoY Change
Revenue from Operations	1,470.49	1,300.89	13.04%	2,967.51	2,053.59	44.50%
Total Income	1,495.68	1,356.06	10.30%	2,992.61	2,087.97	43.33%
EBITDA	2,861.29	2,592.49	10.37%	5,398.02	5,735.95	-5.89%
Profit Before Tax	1,596.21	1,244.85	28.22%	3,048.72	2,263.26	34.70%
Profit After Tax	1,110.92	946.49	17.37%	2,294.29	1,659.62	38.24%
EPS (Basic) in ₹	3.53	3.36	5.06%	7.27	5.95	22.18%

Operational Performance

Bajaj Healthcare demonstrated strong growth in the second quarter of FY26, with revenue from operations reaching ₹1,470.49 crore, marking a 13.04% increase compared to the same quarter last year. The company's total income for Q2 FY26 stood at ₹1,495.68 crore, up by 10.30% year-on-year.

The company's profitability showed significant improvement, with profit before tax (PBT) increasing by 28.22% to ₹1,596.21 crore in Q2 FY26, compared to ₹1,244.85 crore in Q2 FY25. Profit after tax (PAT) rose by 17.37% to ₹1,110.92 crore, reflecting the company's ability to maintain profitability amidst market challenges.

Half-Yearly Performance

For the first half of FY26, Bajaj Healthcare reported impressive growth in its financials. Revenue from operations surged by 44.50% to ₹2,967.51 crore, compared to ₹2,053.59 crore in H1 FY25. The company's PAT for H1 FY26 stood at ₹2,294.29 crore, a substantial increase of 38.24% from the previous year.

Earnings Per Share and Equity

The company's earnings per share (EPS) for Q2 FY26 improved to ₹3.53, up from ₹3.36 in the same quarter last year. For H1 FY26, the EPS reached ₹7.27, showcasing a robust 22.18% growth compared to H1 FY25.

As of September 30, 2025, Bajaj Healthcare's total equity stood at ₹48,639.34 crore, with a share capital of ₹1,579.16 crore and other equity of ₹47,060.18 crore.

Discontinued Operations

The company reported a loss of ₹133.94 crore from discontinued operations for the quarter. This is related to the company's decision in the previous fiscal year to sell or dispose of certain undertakings and industrial lands.

Corporate Actions

In April 2025, Bajaj Healthcare acquired Genrx Pharmaceuticals Private Limited (in Liquidation) for a total consideration of ₹1,085 lakhs. The company has filed an application with the National Company Law Tribunal (NCLT) in Mumbai for necessary reliefs and concessions for the effective implementation of this acquisition.

Conclusion

Bajaj Healthcare's Q2 FY26 results demonstrate the company's resilience and growth potential in the pharmaceutical sector. With strong revenue growth and improved profitability, the company appears well-positioned to capitalize on market opportunities and navigate challenges in the coming quarters.